News
Alabama Raises the Stakes: Higher Penalties Signal a Tougher Era for Pharmaceutical Compliance
For pharmaceutical companies, a regulatory violation has always carried consequences. But in Alabama the potential financial consequences of discipline are about to become much more significant. The Alabama State Board of Pharmacy has adopted new civil penalty...
Regulatory Changes Do Not Stop at Your State Lines: Why Pharmaceutical Companies Must Continuously Monitor Compliance Changes Across Their Supply Chain
The regulatory landscape for pharmaceutical and medical device companies is not static. State boards of pharmacy, departments of health, controlled substance authorities, and other regulatory agencies are continually issuing new requirements, revising existing...
Puerto Rico’s GLP-1 Registration Landscape: Why FDA Approval Matters for Peptide Products
The demand for GLP-1 medications has transformed the pharmaceutical marketplace. Manufacturers, distributors, compounding pharmacies, telehealth organizations, and other healthcare businesses are racing to meet demand for products containing semaglutide,...
Why Proactive State Licensing Is Becoming a Competitive Advantage for CMOs and CDMOs
For years, many contract manufacturing organizations (CMOs) and contract drug manufacturing organizations (CDMOs) viewed state pharmaceutical licensing as a reactive process. If they were not shipping prescription drugs into a particular state, obtaining a license...
The Hidden DSCSA Compliance Risk: Why Verifying Incoming Trading Partners Matters Just as Much as Outgoing Shipments
For pharmaceutical manufacturers, wholesale distributors, repackagers, third-party logistics providers, and dispensers, the Drug Supply Chain Security Act (DSCSA) has fundamentally changed how products move through the supply chain. Most organizations have invested...
Your License Portfolio Is Only as Strong as the Assessment Behind It
When pharmaceutical companies evaluate their state licensing compliance, the conversation often begins with a simple question: "Do we have all the licenses we need?" Unfortunately, that question alone is not enough. The more important question is whether the licenses...
Beyond the Application: Building a Successful Wholesale Distributor Licensing Strategy
Expanding pharmaceutical distribution capabilities is an exciting milestone for any organization. Whether launching a new wholesale distribution business, expanding into additional markets, or bringing distribution operations in-house, licensing is one of the first...
Expanding into Puerto Rico? Here’s What Pharmaceutical Companies Need to Know Before Entering the Market
For pharmaceutical manufacturers, wholesale distributors, virtual manufacturers, and other regulated pharma organizations, Puerto Rico represents an important extension of the U.S. marketplace. However, one of the most common misconceptions companies make is assuming...
Employee Screening for Controlled Substance Access: The Compliance Requirement Too Many Companies Take for Granted
In highly regulated pharmaceutical operations, companies invest significant time and resources into physical security, inventory controls, DEA registrations, and state licensing requirements. Yet one of the most important safeguards protecting controlled...